|
Item |
Description |
|
1 |
When the prescriber writes the eosinophils as 0.3, how is this entered in OPA?
The eosinophil count is entered in OPA as 300. Prescribers may use different units to those written in the restriction. Other examples include:
-
1.1 is entered as 1100, and
-
0.15 is entered as 150
|
|
2 |
Are patients able to change from dupilumab 200mg to dupilumab 300mg?
No. Increasing from 200mg and 300mg strengths is not permitted. The respective strengths are PBS approved for different patient cohorts.
|
|
3 |
Are patients able to change from dupilumab 300mg to dupilumab 200mg?
Yes. Decreasing strength can be approved as continuing treatment.
|
|
4 |
What is the correct process when the ACQ-5 is done after the date of prescribing and OPA is rejecting with reason code 812?
Confirm all other answers are correct using the appropriate Q+As resources. Override the rejection for an ACQ-5 that is:
-
dated after date of prescribing or on and before date of lodgement
-
not future dated (ACQ-5 is not after the date of lodgement)
|
|
5 |
If a patient has a break in therapy and wishes to continue with the same agent, can this be approved?
The prescriber must submit a continuing request including, an ACQ-5 assessment conducted within 4 weeks of the last dose of biological medicine.
There is no requirement on a continuing application for the ACQ-5 to be current.
|
|
6 |
If a script is written for the omalizumab syringe, can the pharmacy supply the pen formulation?
Yes, the pen and syringe form types are equivalent for the purposes of substitution by the pharmacy.
|
|
7 |
Can a paediatric patient be approved for the omalizumab pen formulation?
No, the omalizumab pen device is not intended for use in children below 12 years of age. For children below 12 years of age, the omalizumab syringe is the appropriate form for this population. The pen device is not PBS listed for paediatric patients and pharmacies cannot substitute for the pen.
|
Expand all
PBS SA restriction and item codes